AJCC Cancer Staging in Provider Notes
With this enhancement in the Chemotherapy Manager, the user is able to associate the documented cancer stage information of patients with the provider note.
With this enhancement in the Chemotherapy Manager, the user is able to associate the documented cancer stage information of patients with the provider note.
With this enhancement in the Chemotherapy manager, when the user adds a hydration drug to a patient's plan, the software instantly adds the "E86.0 Dehydration" diagnosis. This helps in ensuring that this diagnosis doesn't get missed when creating a super bill.
With this enhancement in the Chemotherapy Manager, icons including Vitals, Adverse Events and Performance Status have been introduced to the flowsheet navigation bar. This functionality helps the users to add vitals, performance status and adverse events directly from flowsheet.
With this enhancement in the Chemotherapy Manager, the user is able to hide or display different flowsheet modules in flowsheet customizations. This ensures the user can view the relevant module and hide other modules that are not needed for the time being.
Following enhancements have been incorporated to the flowsheet in regards to the user experience:
Patient tags have been introduced in the Chemotherapy Manager to ensure that all patient tags relevant to a patient profile are displayed in the chemotherapy manager. This enhancement helps in compiling the information when the user looks up a patient, an order or an admin by leveraging the relevant tags.
Following are the enhanced areas in this feature:
With this enhancement, the system supports the latest versions of the American Joint Committee on Cancer (AJCC) cancer staging (versions 8 and 9). This ensures that through the AJCC cancer staging, the healthcare professionals have the ability to document the clinical data related to a patient's cancer stage.
Enhancements have been made to the Adverse Events Module in the Chemotherapy Manager including Resolution Reason for Adverse Event, Serious Adverse Event and Relationship Section.
In line with new CMS guidelines effective July 1, 2023, healthcare practices need to use the JZ modifier when billing for drugs, specifically when no amount is discarded from a single-dose container. This requirement applies to all such claims that are submitted by the practices. Hence, to ensure that the billing process complies with this requirement, JZ modifier has been introduced to the Chemotherapy Manager.
With this enhancement, practices have the ability to set precise limits for Serum Creatinine values and Creatinine Clearance levels when determining AUC-based drug dosing. By customizing these limits, healthcare providers can ensure personalized and effective patient care.